The extent of channelling bias when assessing the impact of antiretrovirals on cardiovascular events in HIV-positive pat

评估抗逆转录病毒药物对艾滋病毒阳性患者心血管事件的影响时的通道偏差程度

• 批准号: G0701639/1
• 负责人: Colette Smith
• 金额: $ 30.5万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2008
• 资助国家: 英国
• 起止时间: 2008 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0701639%2F1
• 关键词: extent; channelling; bias; when; assessing

HIV-positive patients are usually treated with a combination of drugs known as highly active antiretroviral therapy (HAART). HAART has led to dramatic decreases in the number of patients dying from HIV and AIDS. However, some of these drugs can cause severe side effects, including heart disease. It is not known whether some drugs are more likely to cause this than others. When comparing the rate of heart disease in those receiving different drugs, we must remember that patients prescribed a particular drug may differ from those prescribed another drug. Patients already at high risk of heart disease (because of their age, sex, or family history) may be selectively given drugs that are not thought to be linked to heart disease. Also, these patients may have more regular cholesterol tests than those thought to be at lower risk. As many approaches to the analysis of these data rely on the fact that similar amounts of information are available from all patients, there is a potential that the results may be unreliable. The aim of this project is to investigate methods that can give a reliable assessment of whether different HIV drugs have a different effect on the development of heart disease.

HIV阳性患者通常使用一种称为高效抗逆转录病毒疗法(HAART)的药物组合进行治疗。HAART导致死于艾滋病毒和艾滋病的患者数量大幅减少。然而，其中一些药物可能会导致严重的副作用，包括心脏病。目前尚不清楚某些药物是否比其他药物更有可能导致这种情况。当比较接受不同药物的患者的心脏病发病率时，我们必须记住，患者开出的特定药物可能与开出的另一种药物不同。已经处于心脏病高危状态的患者(因为他们的年龄、性别或家族病史)可能会被选择性地给予不被认为与心脏病有关的药物。此外，这些患者可能会比那些被认为风险较低的患者进行更多的定期胆固醇测试。由于分析这些数据的许多方法依赖于这样一个事实，即所有患者都可以获得类似数量的信息，因此结果可能不可靠。该项目的目的是研究能够对不同的艾滋病毒药物是否对心脏病的发展有不同影响的可靠评估方法。